Algeta appoints Dr. Donald Coppen as Business Development Director

05-May-2011 - Norway

Algeta ASA announced that it has appointed Donald Coppen as business development Director.

Dr. Coppen will join Chief Business Officer Roger Harrison in driving Algeta's business development strategy aimed at advancing its Thorium payload technology for creating novel targeted cancer therapies, and expanding the Company's pipeline of product candidates.

Dr. Coppen joins Algeta from Biocompatibles International (now part of BTG plc), a UK-based oncology company developing drug-device combination products, where he was Director, Partnering & Licensing. He has previously held project leadership and managerial roles at Lonza Biologics in the UK, and within the crop protection division of Cyanamid International, part of Wyeth (now Pfizer), in Belgium.

Dr. Coppen has a PhD from the University of Southampton and a MBA from the Cranfield School of Management.

Other news from the department people

Most read news

More news from our other portals

So close that even
molecules turn red...